



# Nanoparticle Promising Therapeutic Strategy For The Treatment Of Infective Endocarditis

Vaijayanti Vijay Kakade\*1 Sonal Shinde\*2 Vikas B Wamane\*2

\*Name of student.

\*Name of Assistant Professor.

## ABSTRACT:


Infective endocarditis (IE) has been diagnosed as a biofilm-associated disorder brought about and harm the coronary heart valves and endocardium. There are many problems and demanding situations with inside the antimicrobial remedy of IE, along with multi-drug resistant pathogens, big dose of drug management with following aspect effects, and terrible prognosis. For the beyond few years, the improvement of nanotechnology has promoted using nanoparticles as antimicrobial nano-prescription drugs or novel drug shipping systems (NDDS) in antimicrobial remedy for continual infections and biofilm-associated infectious disorder as those molecules show off numerous advantages. Therefore, nanoparticles have a capacity function to play in fixing issues with inside the remedy of IE, along with enhancing antimicrobial activity, growing drug bioavailability, minimizing frequency of drug management, and stopping aspect effects. In this article, we overview the today's advances in nanoparticles in opposition to drug-resistant micro organism in biofilm and recommends nanoparticles as an opportunity method to the antibiotic remedy of infective endocarditis.

**Keyword:** Infective Endocarditis, Nanoparticle, Nanotechnology.

## Introduction:

Nanotechnology is a novel method of producing and manipulating substance at the molecular scale, which can provide for more efficiently functioning mechan-ical, chemical, and biological components and bring great value to the develop-ment of medicine . The term “nano,” first presented by the famous material scientist Richard P. Feynman in 1959, is a unit used to describe 10<sup>-9</sup> of parameter in the microcosm. Over the past

few years, nanotechnology has sparked intense interest among scientists and has been used to overcome biomedical difficulties and treat various diseases such as cancers, infectious diseases, and cardiovascular diseases. Nanoparticles, nano-carriers or nano-materials, defined as substances with a size of 1 to 100 nm, have specific functions at the cellular, atomic and molecular levels and are widely used in the fields of diagnosis and treatment of diseases. [1]



## Applications of Nanotechnology:

Applications of nanotechnology for treatment, diagnosis, monitoring, and control of bio-logical systems has recently been referred to as “nano-medicine” by the National Institutes of Health. Re-search into the rational delivery and targeting of pharmaceutical, therapeutic, and diagnostic agents is at the forefront of projects in nanomedicine. These involve the identification of precise targets (cells and receptors) related to yspecific clinical conditions and choice of the appropriate nanocarriers to achieve the required responses while minimizing the side effects. Mononuclear phagocytes, dendritic cells, endothelial cells, and cancers (tumour cells, as well as tumour neo-vasculature) are key targets. Today, nanotechnology and nanoscience approaches to particle design and formulation are beginning to expand the market for many drugs and are forming the basis for a highly profitable niche within the industry, but some predicted benefits are hyped. This article will highlight rational approaches in design and surface engineering of nanoscale vehicles and entities for site-specific drug delivery and medical imaging after parenteral administration. Potential pitfalls or side effects associated with drug.[2]

## Definition of infective endocarditis:

An infection caused by bacteria that enter the bloodstream and settle in the heart lining, a heart valve or a blood vessel. Infective endocarditis (IE) is an infectious disease defined by an infection of the heart valve and the endocardial surface, such as a prosthetic heart valve or an indwelling cardiac device.[3]. Infective endocarditis occurs worldwide, and is defined by infection of a native or prosthetic heart valve, the endocardial surface, or an indwelling cardiac device. The causes and epidemiology of the disease have evolved in recent decades with a doubling of the average patient age and an increased prevalence in patients with indwelling cardiac devices. The microbiology of the disease has also changed, and staphylococci, most often associated with health-care contact and invasive procedures, have overtaken streptococci as the most common cause of the disease. Although novel diagnostic and therapeutic strategies have emerged, 1 year mortality has not improved and remains at 30%, which is worse than for many cancers. Logistical barriers and an absence of randomised trials hinder clinical management, and longstanding controversies such as use of antibiotic prophylaxis remain unresolved. In this Seminar, we discuss clinical practice, controversies, and strategies needed to treatment..




Fig.1 Infective Endocarditis.

## **Application of nanoparticle enclosed herbal medicine for the treatment of infective endocarditis:**

Plants are frequent source of medicines. Plants synthesizes a wide range of bioactive materials from its parts such as leaves, stem, bark, latex, root, seeds and flower, known as the secondary metabolites, that are involved in plants defence mechanism against microorganisms, insects and herbivores. Bioactive molecules localize in plants are alkaloids, saponins, tannins, flavonoids, cardiac glycosides, steroids, terpenoids, phenolic compounds, and many more .[5].

### **History and development of herbal medicine**

Natural products, such as plants, have been the fundamental of human disease treatment. The main concept of the development of modern medicine can be traced to traditional medicine and therapies .In several parts of the world like Africa, America, ancient China, Egypt, and India, plants had been employed for medicinal use long before recorded history. Chemical analysis first became accessible in the early 19th century which begins the extraction and modification of herbal extract.

### **Infective endocarditis epidemiology in global trends:**

The global epidemiology of infective endocarditis is becoming better understood with the initiation of multi-centre collaborative studies and with an increasing number of case series being reported from countries outside North America and Europe. However, there are still many knowledge gaps and a lack of population-based data. For endocarditis in developed countries, the role of rheumatic heart disease as a predisposing factor is diminishing; the population is increasingly elderly, staphylococci are becoming much more important pathogens, and proportionally more are healthcare-associated. In developing countries, the epidemiology of infective endocarditis remains similar to North America and Europe from the middle of the twentieth century, affecting a younger age group, is often associated with rheumatic heart disease, and is predominantly caused by streptococci. [6].

### **Infective endocarditis, an infectious disease related to bio-film formation:**

The healthy cardiac endothelium has the ability to resist frequent bacteraemia. However, when the endocardium is damaged by factors, such as rheumatic valvulitis, valve sclerosis, and direct bacterial activity; IE occurs with a series of pathological changes in the endocardium [7]. In general, the typical pathological change observed in endocarditis is the occurrence of vegetation, which in essence is composed of microorganisms combined with platelet-rich thrombi and in-inflammatory leucocytes .The pathogenesis of endocarditis is described below. When the heart valve is injured, the injured endocardial surface promotes platelets and fibrin to form thrombi at the injury site. The microorganisms then accumulate and adhere to the thrombus, followed by the formation of microcolonies. Finally, with the accumulation of microcolonies, the vegetation biofilm becomes mature and causes embolization if it detaches from the biofilm[8].





Fig.2 Biofilm formation .



**Fig.3. Biofilm formation in infective endocarditis .**

### **Type of infective endocarditis:**

1).Non- infective endocarditis:

A) Rheumatic endocarditis.


B) Verrucous ( Libman Sacks) Endocarditis : with SEL.

C) Non- bacterial thrombotic endocarditis.

## [2]. Infective Endocarditis:

A) Acute infective endocarditis.

B) sub – acute infective endocarditis.



## Need for novel drug delivery system “Nano carriers” for “Herbal remedies”

Before getting to the blood stream, many phytochemicals of the herbal drugs will be decomposed plying through the highly acidic pH of the stomach and liver enzymatic action. Thus, the optimum amount of the herbal drugs may not get to the blood. If an optimum quantity of the drug does not reach the infected region at “minimum effective level,” then it will not be potent enough to elucidate a therapeutic effect. Nanocarriers for herbal remedies is capable of carrying an optimum amount of the drug .

## Recent herbal-nanoparticles development

Nanoparticles development has come forward to be a great approach for drug delivery in the treatment of several diseases such as cancer by transversing the reticuloendothelial system, enhanced permeability, tumour-specific targeting, and retention effect.[9].

Currently, pharmaceutical scientists have moved their focus to fabricating a DDS for herbal medicines using scientific methods. *Cuscuta chinensis* is a known traditional Chinese medicine for treatment.

## Mechanism of antimicrobial nanoparticles:

Metallic antimicrobial nanoparticles harm the membrane, for this reason growing permeability. Some nanoparticles immediately engage with the bacterial cellular wall and disturb the everyday feature of cells, for this reason killing microorganisms and inhibiting biofilm formation. Several metallic antimicrobial nanoparticles (NPs) along with silver NPs (AgNPs) (83), gold NPs (84), ZnO NPs (85, 86), and copper oxide NPs (71) inhibit the improvement of biofilms. For example, AgNPs is understood to eliminate the biofilms of *Escherichia coli* (*E. coli*). The fatty acid content material of *E. coli* cells is appreciably decreased, suggesting that the integrity of the bacterial cellular membrane is broken through the AgNPs. In addition, membrane puncturing and cellular lysis may be determined the usage of electron microscopy.. The metal antimicrobial nanoparticles are able to inhibiting biofilm formation and killing micro organism thru sever- al mechanisms. Some metal nanoparticles along with AgNPs and ZnO NPs, harm the membrane, for this reason growing membrane permeability. AgNPs bind to, destabilize, and disrupt the cellular membrane .. A preceding examine confirmed that Zn<sup>+</sup> from ZnO NPs interacts with the cellular membrane, main to reactive oxygen species (ROS) manufacturing and membrane disorganization . Metallic antimicrobial nanoparticles inhibit protein expressions and have an effect on cell features. For ex- ample, Ag<sup>+</sup> is able to interacting with the ribosome band, inhibiting the expression of essential enzymes and proteins required for ATP manufacturing .. ZnO NPs inhibit cytosolic protein expression and the increase of *Bacillus subtilis* (*B. sub- tilis*) cellular, for this reason affecting viability and biofilm formation . Nanoparticles sporting more than one antimicrobial sellers as novel drug transport structures exert synergistic effects. Nanocarriers are transports used to feature as novel drug transport structures for numerous varieties of antibiotics, exerting a synergistic effect .The antimicrobial pastime of nano- providers specifically is based at the excessive floor place to quantity ratio and the residences of numerous additives they deliver .Nanoparticle-primarily based totally drug transport structures are capable of enhancing solubility and balance of medicine and prolonging drug circulation. Nanocarriers engineered to be activated through stimulating elements along with pH and ligands offer sustained and focused drug launch on the web page of infection. In addition, nanoparticle-primarily based totally tablets had been administrated in an infective way to limit the management frequency and facet effects, for this reason enhancing affected person compliance. Nanocarriers packaging more than one antimicrobial sellers have appreciably elevated antimicrobial pastime due to the fact they depend upon the general and synergistic features of its active additives .All additives of nanoparticles ex- hibit synergistic actions, thereby enhancing the therapeutic value. Because few micro organism are proof against all additives of composite nanoparticles, composite nanoparticles are precious remedies for resistant micro organism. Ruby found that copper oxide nanoparticles synergistically mixed with amoxiclav showcase a appreciably advanced antimicrobial pastime because the minimal inhibitory awareness of amoxiclav towards *Proteus mirabilis* (*P. mirabilis*) and *S. aureus* was appreciably reduced. Likewise, the efficacy of polymyxin B mixed with AgNPs towards *P. aeruginosa* biofilms was advanced numerous instances in comparison with unaided polymyxin B [10].




## Diagnosis

To diagnose endocarditis, a health care provider does a physical exam and asks questions about your medical history and symptoms. Tests are done to help confirm or rule out endocarditis.


## Tests

Tests used to help diagnose endocarditis include:

- **Blood culture test.** This test helps identify germs in the bloodstream. Results from this test help determine the antibiotic or combination of antibiotics to use for treatment.
- **Complete blood count.** This test can determine if there's a lot of white blood cells, which can be a sign of infection. A complete blood count can also help diagnose low levels of healthy red blood cells (anemia), which can be a sign of endocarditis. Other blood tests also may be done.
- **Echocardiogram.** Sound waves are used to create images of the beating heart. This test shows how well the heart's chambers and valves pump blood. It can also show the heart's structure. Your provider may use two different types of echocardiograms to help diagnose endocarditis.



**Electrocardiogram :** This quick and painless test measures the electrical activity of the heart. During an ECG, sensors (electrodes) are attached to the chest and sometimes to the arms or legs. It isn't specifically used to diagnose endocarditis, but it can show if something is affecting the heart's electrical activity.

- 
- **Chest X-ray.** A chest X-ray shows the condition of the lungs and heart. It can help determine if endocarditis has caused heart swelling or if any infection has spread to the lungs.

**Computerized tomography (CT) scan or magnetic resonance imaging (MRI).** You may need scans of your brain, chest or other parts of your body if your provider thinks that infection has spread to these areas [11].

## Symptoms:

Symptoms of endocarditis can vary from person to person. Endocarditis may develop slowly or suddenly. It depends on the type of germs causing the infection and whether there are other heart problems.

Common symptoms of endocarditis include:

- 1) Aching joints and muscles
- 2) Chest pain when you breathe
- 3) Fatigue
- 4) Flu-like symptoms, such as fever and chills
- 5) Night sweats
- 6) Shortness of breath
- 7) Swelling in the feet, legs or belly
- 8) A new or changed whooshing sound in the heart (murmur)

Less common endocarditis symptoms can include:

- Unexplained weight loss
- Blood in the urine
- Tenderness under the left rib cage (spleen)
- Painless red, purple or brown flat spots on the soles bottom of the feet or the palms of the hands (Janeway lesions)
- Painful red or purple bumps or patches of darkened skin (hyperpigmented) on the tips of the fingers or toes (Osler nodes)
- Tiny purple, red or brown round spots on the skin (petechiae), in the whites of the eyes or inside the mouth.[12].

## Treatment:

Many people with endocarditis are successfully treated with antibiotics. Sometimes, surgery may be needed to fix or replace damaged heart valves and clean up any remaining signs of the infection.

## Medications:

- 1).The type of medication you receive depends on what's causing the endocarditis.
- 2).High doses of IV antibiotics are used to treat endocarditis caused by bacteria. If you receive IV antibiotics, you'll generally spend a week or more in the hospital so that care providers can determine if the treatment is working.
- 3).Once your fever and any severe symptoms have gone away, you might be able to leave the hospital. Some people continue IV antibiotics with visits to a provider's office or at home with home care. Antibiotics are usually taken for several weeks.
- 4).If endocarditis is caused by a fungal infection, antifungal medication is given. Some people need lifelong antifungal pills to prevent endocarditis from returning.[13].

## Drugs for Infective Endocarditis

A comprehensive list of drugs used to treat Infective Endocarditis are listed here. View list of drugs used to treat 'Infective Endocarditis'. Click below on the listed drug to know more and this includes the brand name(s), price of the drug, its dosage, side-effects, adverse events, how and when should it be taken.

### Generic and Trade Names of Drugs for Treatment of Infective Endocarditis

For the convenience of the medical practitioners we have listed both the generic name and the multiple brand names of the drugs for Endocarditis Infection.

### Ampicillin

Ampicillin is beta-lactam antibiotic, prescribed for certain types of bacterial infections such as UTI, meningitis, gonorrhoea, pneumonia, bronchitis, ear, lung, skin and respiratory tract infections.

### Trade Names :

Broacil | Ingacillin | Campicilin Plus | Ampital | Ampicillin (Jagsonpal) | Jp - Cilin | Campicilin | Ampisyn | Ampilac | Biocilin

### Cefazolin:

Cefazolin is a cephalosporin antibiotic, mainly used to treat bacterial infections in different parts of the body (the lung, bone, joint, stomach, blood, heart valve, and urinary tract).

### Trade Names :

Azolin | Reflin | Cefadin | Orizolin | Reflin | Cefadin | Orizolin | Azolin | Reflin | Cefadin

### Ceftazidime

Ceftazidime is a cephalosporin antibiotic, prescribed for certain types of bacterial infections.

**Trade Names :**

3A-Taz® [Vial] | 3A-Taz® [Vial] | Afzid® [Vial] | Afzid® [Vial] | Afzid® [Vial] | Amceft® [Tab] | Amceft® [Tab] | Aritaz® [Vial] | Aritaz® [Vial] | Azid Inj® [Vial]

**Ceftriaxone**

Ceftriaxone is indicated for: Lower Respiratory Tract Infections Skin infections Urinary Tract Infections Pelvic Inflammatory Disease –infections related to the female genital tract Bacterial Septicemia-infection in the blood Bone and Joint Infections Meningitis Surgical Prophylaxis –To prevent infections during surgery .

**Trade Names :**

Encef | Malocef | Winceft | Zetox | Corcef | Taxone -XP | Glen Tzb | Eftrio T | Arcef XP | Cefamed T 1.125

**More...****Daptomycin**

Daptomycin is an antibiotic, prescribed for serious infections.

**Gentamicin**

Gentamicin is an antibiotic, prescribed for severe bacterial infections.

**Trade Names :**

Gentalin (Eye) (5 ml) | Gentamycin (5 ml) | Gentalab (E/E) (10 ml) | Gentyric (E/E) (5 ml) | Emugent (Eye) (5 ml) | Gentamide (Eye) (5 ml) | Gentamax (Eye) (5 ml) | Genbiotic (E/E) (5 ml) | Gentapar (5 ml) | G Mycin (E/E) (5 ml)

**More...****Metronidazole**

Metronidazole is an antibacterial agent, prescribed for trichomoniasis, amebiasis and other bacterial infections.

**Trade Names :**

Oflomac-M (50mg/100mg) | Oflomac-M Forte (100mg/200mg) | Oflostar-M (50mg/100mg/5mL) | Aldezole (200mg) | Aldezole (400mg) | Aldezole (200mg/5mL) | Aldezole (200mg/5mL) | Flagyl (200mg) | Flagyl (400mg) | Flagyl (200mg/5mL)

**More...****Penicillin v Potassium**

Penicillin v Potassium is an antibiotic, prescribed for certain types of bacterial infections.

## Rifampin

Rifampin is a rifamycin antibiotic, prescribed for tuberculosis (TB).

## Tobramycin

Tobramycin is an aminoglycoside antibiotic, prescribed for the management of cystic fibrosis.

### **Trade Names :**

Bactob (80mg/2ml) | Tobaprex (80mg/2ml) | Tobazest INJ (80mg/2ml) | Eyebrex (0.3%) | TOB-Clear (0.3% w/v) | Tobaprex Eye DPS (0.3% w/v) | Tobasafe (0.3%) | Tobazest (0.3% w/v) | Tozen (0.3%) | Tobaflam (0.3% w/v + 0.5w/v/mL)

### **More...**

## Vancomycin


Vancomycin is a glycopeptide antibiotic, prescribed for serious bacterial infections, endocarditis and surgical prophylaxis in major procedures.

### **Trade Names :**

Vancorid CP | Vanacin -CP | Vantox CP (1 gm) | Vansafe | Vanacin (1 gm) | Viovan (1gm) | Vancoled (1gm) | Vancocare | Covancin (1gm) | Vancorin

### **Mechanism of infective endocarditis:**

Patients with infective endocarditis (IE) form a heterogeneous group, ranging from those who are successfully treated with no adverse events, to those with severe complications and a high mortality. In this Review, we highlight pathogen–host interactions and the mechanisms underlying various risk factors for patients with IE. A temporal trend in the pattern of IE has been observed in high-income countries within the past 5 decades, with patients contracting IE at an increasingly old age, and a growing incidence of health-care-associated staphylococcal IE. Consequently, prevention strategies should no longer focus on prophylaxis of streptococcal bacteraemia during dental procedures, but instead encourage a more-general approach to reduce the incidence of health-care-associated IE. Much knowledge has been gained about the mechanisms of vegetation formation, growth, and embolization on damaged or inflamed cardiac valves, and on cardiac devices. Improved understanding of these mechanisms will help to combat the increasing problem of antimicrobial resistance. Two mechanisms of IE should increasingly be the focus of future research: the role of immunosenescence in elderly patients with IE, particularly after transcatheter aortic valve implantation, and the mechanisms that trigger septic shock, a condition that leads to a substantial increase in the risk of death in patients with IE.[14].




**Fig.4 .Mechanisms of infective endocarditis.**

### **Pathogenesis of infective endocarditis:**

The pathophysiology of infective endocarditis comprises at least three critical elements: preparation of the cardiac valve for bacterial adherence, adhesion of circulating bacteria to the prepared valvular surface, and survival of the adherent bacteria on the surface, with propagation of the infected vegetation. It appears that circulating bacteria do not readily adhere to normal endothelial surfaces. Trauma to the valve, however, produces an alteration in the endothelial cells, leading to either disruption of the surface and deposition of platelets and fibrin, or other phenomena that render the surface susceptible to colonization by circulating bacteria. Once the surface is prepared, some bacterial strains appear to adhere to the fibrin-platelet matrix more avidly than others. The bacterial virulence factors that promote adherence are complex, but at least one, an extracellular polysaccharide (dextran), has been identified. Adherence can be blocked by antibodies directed against various surface structures. The survival of bacteria adherent to the surface of the vegetation appears to be complex as well, requiring resistance in situ to the bactericidal properties of complement and phagocytosis by white cells. In addition, vegetation propagation involves activation of the clotting cascade. For at least some streptococci, this occurs partly through perturbation of the valvular cells to produce tissue factor (tissue thromboplastin), which results in the deposition and growth of a fibrin-platelet clot over the rapidly growing bacterial colonies.[15].

## Infective Endocarditis: Pathogenesis



**Flowchart 1: Pathogenesis of Infective endocarditis .**

Nano based drug delivery systems: recent developments and future prospects .Nanotechnology is shown to bridge the barrier of biological and physical sciences by applying nanostructures and Nano phases at various fields of science. Specially in nanomedicine and nano based drug delivery systems, where such particles are of major interest. Nanomaterials can be well-defined as a materials with sizes ranged between 1 and 100 nm, which influences the frontiers of nanomedicine starting from biosensors, microfluidics, drug delivery, and micro-ray tests to tissue engineering]. Nanotechnology employs curative agents at the nanoscale level to develop nanomedicine. The field of biomedicine comprising Nano biotechnology, drug delivery, biosensors, and tissue engineering has been powered by nanoparticles .As nanoparticles comprise materials designed at the atomic or molecular level, they are usually small sized nanospheres .Hence, they can move more freely in the human body as compared to bigger materials. Nanoscale sized particles exhibit unique structural, chemical, mechanical, magnetic, electrical, and biological properties. Nanomedicine have become well appreciated in recent times due to the fact that nanostructures could be utilized as delivery agents by encapsulating drugs or attaching therapeutic drugs and deliver them to target tissues more precisely with a controlled release . Nanomedicine, is an emerging field implementing the use of knowledge and techniques of nanoscience in medical biology and disease prevention and remediation. It implicates the utilization of Nano dimensional materials including Nano robots, nanosensors for diagnosis, delivery, and sensory purposes, and actuate materials in live cells .. For example, a nanoparticle-based method has been developed which combined both the treatment and imaging modalities of cancer diagnosis . The very first generation of nanoparticle-based therapy included lipid systems like liposomes and micelles, which are now FDA-approved .These liposomes and micelles can contain inorganic nanoparticles like gold or magnetic nanoparticles .These properties let to an increase in the use of inorganic nanoparticles with an emphasis on drug delivery, imaging and therapeutics functions. In addition, nanostructures reportedly aid preventing drugs from being tarnished in the

gastrointestinal region and help the delivery of sparingly water-soluble drugs to their target location. Nanodrugs show higher oral bioavailability because they exhibit typical uptake mechanisms of absorptive endocytosis.[16].

## Conclusion:

As described above information Infective Endocarditis is related to heart. IE is an infectious disease related to bio-film formation. With the development of nanotechnology, application of nanoparticles has been an alternative strategy for treatment of IE. In this review, applications of several nanoparticles have been explored. Also types of infective endocarditis, their mechanisms, pathophysiology are explored. Prevention is undoubtedly better than cure. Diagnosis and treatment are involved.

Overall, there is still a long road ahead for researchers to explore new and effective nanoparticles to be used in IE. The progress of nanoparticles against biofilm and drug-resistant microbes has greatly improved the therapy of biofilm-related infectious disease. With the development of nanotechnology, the prospect of nanoparticles in the treatment of IE is still promising and exciting.

## Reference :

- 1). Qi Tong, Tao Li, Lu Jiang, Zhengjie Wang, Yongjun Qian. THE ANATOLIAN JOURNAL OF CARDIOLOGY, Nanoparticle, a promising therapeutic strategy for the treatment of infective endocarditis, Accepted: October 5, 2021 Available Online Date: February 2, 2022, [90].
- 2). S. Moein Moghimi,\*, A. Christy Hunter,\* and J. Clifford Murray† Nanomedicine: current status and future prospects, The FASEB Journal, [311].
- 3). Qi Tong, Tao Li, Lu Jiang, Zhengjie Wang, Yongjun Qian. THE ANATOLIAN JOURNAL OF CARDIOLOGY, Nanoparticle, a promising therapeutic strategy for the treatment of infective endocarditis, Accepted: October 5, 2021, Available Online Date: February 2, 2022.
- 4). Mehrdad Namdaria, Biomedicine & Pharmacotherapy. A brief review on the application of nanoparticle enclosed herbal medicine for the treatment of infective endocarditis, Volume 87, March 2017, Pages 321-331, March 2017, Pages 321-331.
- 5). Thomas J Cahill, MRCP. Dr Bernard D Prendergast, FRCP, Published: September 01, 2015 DOI: [https://doi.org/10.1016/S0140-6736\(15\)00067-7](https://doi.org/10.1016/S0140-6736(15)00067-7). Infective endocarditis VOLUME 387, ISSUE 10021P882-893, FEBRUARY 27, 2012.
- 6) Haur Sen Yew et al. Current Infectious Disease, Global trends in infective endocarditis epidemiology. Rep. 2012 Aug.,
- 7) 1. 1. Werdan K, Dietz S, Löffler B, Niemann S, Bushnaq H, Silber RE, et al. Mechanisms of infective endocarditis: pathogen-host interaction and risk states. Nat Rev Cardiol 2014; 11: 35-50. [Crossref]



- 8) Cahill TJ, Prendergast BD. Infective endocarditis. *Lancet* 2016; 387: 882-93, Vestby LK, Grønseth T, Simm R, Nesse LL. Bacterial Biofilm and its Role in the Pathogenesis of Disease. *Antibiotics (Basel)* 2020; 9: 59.
- 9) Mehrdad Namdaria, *Biomedicine & Pharmacotherapy*. A brief review on the application of nanoparticle enclosed herbal medicine for the treatment of infective endocarditis. *Volume 87*, March 2017, Pages 321-331, March 2017, Pages 321-331.
- 10). Qi Tong, Tao Li, Lu Jiang, Zhengjie Wang, Yongjun Qian. *THE ANATOLIAN JOURNAL OF CARDIOLOGY*, Nanoparticle, a promising therapeutic strategy for the treatment of infective endocarditis, Accepted: October 5, 2021 Available Online Date: February 2, 2022, [94,95,96]
- 12 <https://www.mayoclinic.org/diseases-conditions/endocarditis/diagnosis-treatment/drc-20352582>.
- 13). <https://www.mayoclinic.org/diseases-conditions/endocarditis/diagnosis-treatment/drc-20352582>
- 14). Karl Werdan, Sebastian Dietz, Ursula Müller-Werdan, Mechanisms of infective endocarditis: pathogen–host interaction and risk states, Published: 19 November 2013. *Nature Reviews Cardiology*, 11 pages 35–50 (2014).
- 15). P M Sullam et al. *Am J Med*. 1985. Pathogenesis of endocarditis. <https://www.ncbi.nlm.nih.gov/>.
- 16). Jayantha Kumar Patra<sup>1</sup>, Gitishree Das<sup>1</sup>, Leonardo Fernandes Fraceto<sup>2,3</sup>, Estefania Vangelie Ramos Campos<sup>2,3</sup>, Maria del Pilar Rodriguez-Torres<sup>4</sup>, Laura Susana Acosta-Torres<sup>4</sup>, Luis Armando Diaz-Torres<sup>5</sup>, Renato Grillo<sup>6</sup>, Mallappa Kumara Swamy<sup>7</sup>, Shivesh Sharma<sup>8</sup>, Solomon Habtemariam<sup>9</sup> and Han-Seung Shin<sup>10\*</sup>, Nano based drug delivery systems: recent developments and future prospects. *Journal of Nanobiotechnology*. Patra et al. *J Nanobiotechnol* (2018) 16:71 <https://doi.org/10.1186/s12951-018-0392-8>.
- 17). <https://www.medindia.net/index.asp.MDMEDINDIA>.